Cite

HARVARD Citation

    Diamond, B. et al. (2021). Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet. 8 (6), pp. e422-e432. [Online]. 
  
Back to record